← Back to Screener
Reviva Pharmaceuticals Holdings, Inc. Common Stock (RVPH)
Price$0.91
Favorite Metrics
Price vs S&P 500 (26W)-102.21%
Price vs S&P 500 (4W)-3.24%
Market Capitalization$10.89M
All Metrics
Book Value / Share (Quarterly)$1.47
P/TBV (Annual)10.34x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-4.19
Price vs S&P 500 (YTD)-88.91%
EPS (TTM)$-6.74
10-Day Avg Trading Volume0.62M
EPS Excl Extra (TTM)$-6.74
EPS (Annual)$-5.48
ROI (Annual)-219.39%
Cash / Share (Quarterly)$2.46
ROA (Last FY)-124.75%
EBITD / Share (TTM)$-5.56
ROE (5Y Avg)-992.53%
Cash Flow / Share (Annual)$-4.19
P/B Ratio1.26x
P/B Ratio (Quarterly)3.71x
Net Income / Employee (Annual)$-1
Net Interest Coverage (TTM)-3547.29x
ROA (TTM)-162.27%
EPS Incl Extra (Annual)$-5.48
Current Ratio (Annual)2.08x
Quick Ratio (Quarterly)1.98x
3-Month Avg Trading Volume0.48M
52-Week Price Return-94.01%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$-0.38
52-Week High$23.20
EPS Excl Extra (Annual)$-5.48
26-Week Price Return-93.46%
Quick Ratio (Annual)1.98x
13-Week Price Return-87.86%
Total Debt / Equity (Annual)0.05x
Current Ratio (Quarterly)2.08x
Enterprise Value$-3.143
Book Value / Share Growth (5Y)19.99%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$2.46
3-Month Return Std Dev156.63%
Net Income / Employee (TTM)$-1
ROE (Last FY)-229.71%
EPS Basic Excl Extra (Annual)$-5.48
Total Debt / Equity (Quarterly)0.05x
EPS Incl Extra (TTM)$-6.74
ROI (TTM)-108.47%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.60
Price vs S&P 500 (52W)-129.10%
Year-to-Date Return-84.77%
5-Day Price Return-2.19%
EPS Normalized (Annual)$-5.48
ROA (5Y Avg)-131.98%
Month-to-Date Return16.49%
EBITD / Share (Annual)$-5.55
LT Debt / Equity (Annual)0.01x
ROI (5Y Avg)-725.25%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-6.74
P/B Ratio (Annual)3.71x
Book Value / Share (Annual)$1.47
Price vs S&P 500 (13W)-90.72%
Beta0.77x
Revenue / Share (TTM)$0.00
ROE (TTM)-111.82%
52-Week Low$0.59
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.08
4.08
4.08
4.00
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
RVPHReviva Pharmaceuticals Holdings, Inc. Common Stock | — | — | — | — | $0.91 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Reviva Pharmaceuticals is a late-stage biopharmaceutical company developing therapeutics for central nervous system, inflammatory, and cardiometabolic diseases. Its lead candidate, Brilaroxazine (RP5063), targets multiple neuropsychiatric indications including schizophrenia, bipolar disorder, depression, ADHD, and dementia-related psychosis, with RP1208 also in development. The company uses a chemical genomics-driven platform and proprietary chemistry to discover and develop new medicines.